Retention of virulence following adaptation to colistin in Acinetobacter baumannii reflects the mechanism of resistance

Journal of Antimicrobial Chemotherapy

Volumn 70, Issue 8, 2015, Pages 2209-2216

  Wand, Matthew E ^a   Bock, Lucy J ^a   Bonney, Laura C ^a   Sutton, J Mark ^a  

^a PUBLIC HEALTH ENGLAND   (United Kingdom)

Author keywords

Acinetobacter baumannii; Antibiotic resistance; Colistin adaptation; Galleria mellonella

Indexed keywords

COLISTIN; ANTIINFECTIVE AGENT; BACTERIAL DNA;

ACINETOBACTER BAUMANNII; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL GENE; BACTERIAL GROWTH; BACTERIAL VIRULENCE; BACTERIUM ISOLATE; CONCENTRATION RESPONSE; CONTROLLED STUDY; GALLERIA MELLONELLA; GENE LOCUS; GROWTH RATE; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; ANIMAL; ANIMAL MODEL; CHEMISTRY; DNA SEQUENCE; DRUG EFFECTS; GENETICS; GROWTH, DEVELOPMENT AND AGING; LEPIDOPTERA; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; MUTATION; SURVIVAL; VIRULENCE; VIRUS CULTURE;

ACINETOBACTER BAUMANNII; ANIMALS; ANTI-BACTERIAL AGENTS; COLISTIN; DNA, BACTERIAL; DRUG RESISTANCE, BACTERIAL; GENES, BACTERIAL; LEPIDOPTERA; MICROBIAL SENSITIVITY TESTS; MODELS, ANIMAL; MUTATION; SEQUENCE ANALYSIS, DNA; SERIAL PASSAGE; SURVIVAL ANALYSIS; VIRULENCE;

EID: 84939511257     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkv097     Document Type: Article

References (43)

1. Coelho JM, Turton JF, Kaufmann ME et al. Occurrence of carbapenemresistant Acinetobacter baumannii clones at multiple hospitals in London and Southeast England. J Clin Microbiol 2006; 44: 3623-7.
2. Enoch DA, Summers C, Brown NM et al. Investigation and management of an outbreak of multidrug-carbapenem-resistant Acinetobacter baumannii in Cambridge, UK. J Hosp Infect 2008; 70: 109-18.
3. Livermore DM, Hill RL, Thomson H et al. Antimicrobial treatment and clinical outcome for infections with carbapenem-and multiply-resistant Acinetobacter baumannii around London. Int J Antimicrob Agents 2010; 35: 19-24.
4. Chen Y, Zhou Z, Jiangb Y et al. Emergence of NDM-1-producing Acinetobacter baumannii in China. J Antimicrob Chemother 2011; 66: 1255-9.
5. Pfeifer Y, Wilharm G, Zander E et al. Molecular characterization of blaNDM-1 in an Acinetobacter baumannii strain isolated in Germany in 2007. J Antimicrob Chemother 2011; 66: 1998-2001.
6. Ko KS, Suh JY, Kwon KTet al. High rates of resistance to colistin and polymyxin B in subgroups of Acinetobacter baumannii isolates for Korea. J Antimicrob Chemother 2007; 60: 1163-7.
7. Samonis G, Matthaiou DK, Kofteridis D et al. In vitro susceptibility to various antibiotics of colistin-resistant gram-negative bacterial isolates in a general tertiary hospital in Crete, Greece. Clin Infect Dis 2010; 50: 1689-91.
8. Arduino SM, Quiroga MP, Ramírez MS et al. Transposons and integrons in colistin resistant clones with epidemic or sporadic behaviour. J Med Microbiol 2012; 61: 1417-20.
9. Falagas ME, Rafailidis PI, Matthaiou DK et al. Pandrug-resistant Klebsiella pneumoniae, Pseudomonas aeruginosa and Acinetobacter baumannii infections: characteristics and outcome in a series of 28 patients. Int J Antimicrob Agents 2008; 32: 450-4.
10. Hancock RE. Peptide antibiotics. Lancet 1997; 349: 418-22.
11. Falagas ME, Kasiakou SK. Colistin: the revival of polymyxins for the management of multidrug-resistant gram negative bacterial infections. Clin Infect Dis 2010; 40: 1333-41.
12. Adams MD, Nickel GC, Bajaksouzian S et al. Resistance to colistin in Acinetobacter baumannii associated with mutations in the PmrAB twocomponent system. Antimicrob Agents Chemother 2009; 53: 3628-34.
13. Cheng HY, Chen YF, Peng HL. Molecular characterization of the PhoPQ-PmrD-PmrAB mediated pathway regulating polymyxin B resistance in Klebsiella pneumoniae CG43. J Biomed Sci 2010; 17: 60.
14. Moskowitz SM, Ernst RK, Miller SI. PmrAB, a two-component regulatory system of Pseudomonas aeruginosa that modulates resistance to cationic antimicrobial peptides and addition of aminoarabinose to lipid A. J Bacteriol 2004; 186: 575-9.
15. Trent MS, Ribeiro AA, Lin S et al. An inner membrane enzyme in Salmonella and Escherichia coli that transfers 4-amino-4-deoxy-L-arabinose to lipid A: induction on polymyxin-resistant mutants and role of a novel lipid-linked donor. J Biol Chem 2001; 276: 43122-31.
16. Lee H, Hsu FF, Turk J et al. The PmrA-regulated pmrC gene mediates phosphoethanolamine modification of lipid A and polymyxin resistance in Salmonella enterica. J Bacteriol 2004; 186: 4124-33.
17. Moffatt JH, Harper M, Adler B et al. Insertion sequence ISAba11 is involved in colistin resistance and loss of lipopolysaccharide in Acinetobacter baumannii. Antimicrob Agents Chemother 2011; 55: 3022-4.
18. Moffatt JH, Harper M, Harrison P et al. Colistin resistance in Acinetobacter baumannii is mediated by complete loss of lipopolysaccharide production. Antimicrob Agents Chemother 2010; 54: 4971-7.
19. Andersson DI, Hughes D. Antibiotic resistance and its cost: is it possible to reverse resistance? Nat Rev Microbiol 2010; 8: 260-71.
20. Rolain JM, Roch A, Castanier M et al. Acinetobacter baumannii resistant to colistin with impaired virulence: a case report from France. J Infect Dis 2011; 204: 1146-7.
21. López-Rojas R, Jiménez-Mejías ME, Lepe JA et al. Acinetobacter baumannii resistant to colistin alters its antibiotic resistance profile: a case report from Spain. J Infect Dis 2011; 204: 1147-8.
22. Hraiech S, Roch A, Lepidi H et al. Impaired virulence and fitness of a colistin-resistant clinical isolate of Acinetobacter baumannii in a rat model of pneumonia. Antimicrob Agents Chemother 2013; 57: 5120-1.
23. López-Rojas R, McConnell MJ, Jiménez-Mejías ME et al. Colistin resistance in a clinical Acinetobacter baumannii strain appearing after colistin treatment: effect on virulence and bacterial fitness. Antimicrob Agents Chemother 2013; 57: 4587-9.
24. López-Rojas R, Domínguez-Herrera J, McConnell MJ et al. Impaired virulence and in vivo fitness of colistin-resistant Acinetobacter baumannii. J Infect Dis 2011; 203: 545-8.
25. Wand ME, Bock LJ, Turton JF et al. Acinetobacter baumannii virulence is enhanced in Galleria mellonella following biofilm adaptation. J Med Microbiol 2012; 61: 470-7.
26. Park YK, Choi JY, Shin D et al. Correlation between overexpression and amino acid substitution of the PmrAB locus and colistin resistance in Acinetobacter baumannii. Int J Antimicrob Agents 2011; 37: 525-30.
27. Wand ME, Müller CM, Titball RW et al. Macrophage and Galleria mellonella infection models reflect the virulence of naturally occurring isolates of B. pseudomallei, B. thailandensis and B. oklahomensis. BMC Microbiol 2011; 11: 11.
28. Peleg AY, Jara S, Monga D et al. Galleria mellonella as a model system to study Acinetobacter baumannii pathogenesis and therapeutics. Antimicrob Agents Chemother 2009; 53: 2605-9.
29. Zimbler DL, Park TM, Arivett BA et al. Stress response and virulence functions of the Acinetobacter baumannii NfuA Fe-S scaffold protein. J Bacteriol 2012; 194: 2884-93.
30. Lean SS, Suhaili Z, Ismail S et al. Prevalence and genetic characterization of carbapenem-and polymyxin-resistant Acinetobacter baumannii isolated from a tertiary hospital in Terengganu, Malaysia. ISRN Microbiol 2014; 2014: 953417.
31. Jander G, Rahme L, Ausbel F. Positive correlation between virulence of Pseudomonas aeruginosa mutants in mice and insects. J Bacteriol 2000; 182: 3843-5.
32. Brennan M, Thomas DY, Whiteway M et al. Correlation between virulence of Candida albicans mutants in mice and Galleria mellonella larvae. FEMS Immunol Med Microbiol 2002; 34: 153-7.
33. Pournaras S, Poulou A, Dafapoulou K et al. Growth retardation, reduced invasiveness, and impaired colistin-mediated cell death associated with colistin resistance development in Acinetobacter baumannii. Antimicrob Agents Chemother 2014; 58: 828-32.
34. Snitkin ES, Zelazny AM, Gupta J et al. Genomic insights into the fate of colistin resistance and Acinetobacter baumannii during patient treatment. Genome Res 2013; 23: 1155-62.
35. Bartling CM, Raetz CRH. Crystal structure and acyl chain selectivity of Escherichia coli LpxD, the N-acyltransferase of lipid A biosynthesis. Biochemistry 2009; 48: 8672-83.
36. Lee CJ, Liang X, Chen X et al. Species-specific and inhibitor-dependent conformations of LpxC: implications for antibiotic design. Chem Biol 2011; 18: 38-47.
37. Badger J, Chie-Leon B, Logan C et al. Structure determination of LpxD from the lipopolysaccharide-synthesis pathway of Acinetobacter baumannii. Acta Crystallogr Sect F Struct Biol Cryst Commun 2013; 69: 6-9.
38. Beceiro A, Moreno A, Fernández N et al. Biological cost of different mechanisms of colistin resistance and their impact on virulence in Acinetobacter baumannii. Antimicrob Agents Chemother 2014; 58: 518-26.
39. Arroyo LA, Herrera CM, Fernandez L et al. The pmrCAB operon mediates polymyxin resistance in Acinetobacter baumannii ATCC 17978 and clinical isolates through phosphoethanolamine modification of lipid A. Antimicrob Agents Chemother 2011; 55: 3743-51.
40. Beceiro A, Llobet E, Aranda J et al. Phosphoethanolamine modification of lipid A in colistin-resistant variants of Acinetobacter baumannii mediated by the pmrAB two-component regulatory system. Antimicrob Agents Chemother 2011; 55: 3370-9.
41. Lesho E, Yoon EJ, McGann P et al. Emergence of colistin-resistance in extremely drug-resistant Acinetobacter baumannii containing a novel pmrCAB operon during colistin therapy of wound infections. J Infect Dis 2013; 208: 1142-51.
42. Kim Y, Bae IK, Lee H et al. In vivo emergence of colistin resistance in Acinetobacter baumannii clinical isolates of sequence type 357 during colistin treatment. Diagn Microbiol Infect Dis 2014; 79: 362-6.
43. Sun S, Negrea A, Rhen M et al. Genetic analysis of colistin resistance in Salmonella enterica serovar Typhimurium. Antimicrob Agents Chemother 2009; 53: 2298-305.